Drugmakers told the FDA that inflexible post-approval change requirements are among the top regulatory barriers to the ...

Agenus Inc. , a leader in immuno-oncology innovation, today announced that France's National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol ...

Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth ...

Potential to Be the First Targeted Fast-Acting Therapy for GBS, Setting a New Standard of Care BLA Submission with U.S./European Data from ...

CrowdStrike today announced it has signed a definitive agreement to acquire SGNL, a leader in Continuous Identity. This acquisition will accelerate CrowdStrike's leadership in Next-Gen Identity ...

Eisai And Nuvation Bio Enter Into Exclusive Licensing Agreement For Taletrectinib In Europe And Additional Countries Outside The U.S., China And Japan. Eisai and Nuvation Bio Enter into Exclusive ...

Strategic collaboration expands taletrectinib global reach with a leading oncology partnerEisai will receive exclusive development, registration and commercialization rights for taletrectinib for the ...

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in ...

Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range ...

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in di ...

MINNEAPOLIS, MN, UNITED STATES, January 11, 2026 /EINPresswire.com/ -- Itiliti Health is proud to announce that South ...

This news release constitutes a “designated news release” for the purposes of the Company’s amended and restated ...